Patient Story

Discover the possibilities for patients like Michelle and Daniel1


Explore the powerful and consistent results across PsA and axSpA1-6

Safety, Dosing, and Access

Learn more reasons to reach for Taltz1

IL-17A=interleukin-17A; PsA=psoriatic arthritis; axSpA=axial spondyloarthritis.

References: 1. Taltz [package insert]. Indianapolis, IN: Lilly USA, LLC. 2. Data on file. Lilly USA, LLC. DOF-IX-US-0190. 3. Mease PJ, Smolen JS, Behrens F, et al; SPIRIT H2H Study Group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123-131. 4. van der Heijde D, Cheng-Chung Wei J, Dougados M, et al; COAST-V Study Group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441-2451. 5. Data on file. Lilly USA, LLC. DOF-IX-US-0013. 6. Data on file. Lilly USA, LLC. DOF-IX-US-0225.